Literature DB >> 12884168

Separate worlds set to collide: smallpox, vaccinia virus vaccination, and human immunodeficiency virus and acquired immunodeficiency syndrome.

Valerianna K Amorosa1, Stuart N Isaacs.   

Abstract

Concerns about the possible release of smallpox by bioterrorists has led to policies that recommend smallpox vaccination of some health care providers, and, in the near future, the vaccine may become available to the general population on a voluntary basis. Both smallpox virus (variola virus) and the smallpox vaccine (vaccinia virus) will have a significant impact on people infected with human immunodeficiency virus (HIV). Given that populations with acquired immunodeficiency syndrome and populations with immunosuppressed conditions due to solid organ and bone marrow transplantation were not present in the days when smallpox was prevalent, we will speculate on how smallpox might present in immunodeficient patients, and we will review the adverse events expected from the smallpox vaccine in hosts with HIV infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12884168     DOI: 10.1086/375823

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

Review 1.  The effects of post-exposure smallpox vaccination on clinical disease presentation: addressing the data gaps between historical epidemiology and modern surrogate model data.

Authors:  M Shannon Keckler; Mary G Reynolds; Inger K Damon; Kevin L Karem
Journal:  Vaccine       Date:  2013-08-27       Impact factor: 3.641

2.  Maximal adjuvant activity of nasally delivered IL-1α requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine production.

Authors:  Afton L Thompson; Brandi T Johnson; Gregory D Sempowski; Michael D Gunn; Baidong Hou; Anthony L DeFranco; Herman F Staats
Journal:  J Immunol       Date:  2012-02-15       Impact factor: 5.422

3.  Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.

Authors:  Koert J Stittelaar; Geert van Amerongen; Ivanela Kondova; Thijs Kuiken; Rob F van Lavieren; Frank H M Pistoor; Hubert G M Niesters; Gerard van Doornum; Ben A M van der Zeijst; Luis Mateo; Paul J Chaplin; Albert D M E Osterhaus
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

4.  A Case Report of Monkeypox in a 4-Year-Old Boy from the DR Congo: Challenges of Diagnosis and Management.

Authors:  Anna Korsgaard Eltvedt; Michael Christiansen; Anja Poulsen
Journal:  Case Rep Pediatr       Date:  2020-04-09

5.  Vaccination in patients with HIV infection.

Authors:  Todd D Gleeson; Mark R Wallace; Sybil A Tasker
Journal:  Curr Infect Dis Rep       Date:  2006-03       Impact factor: 3.663

6.  Use of a recombinant vaccinia virus expressing interferon gamma for post-exposure protection against vaccinia and ectromelia viruses.

Authors:  Susan A Holechek; Karen L Denzler; Michael C Heck; Jill Schriewer; R Mark Buller; Fatema A Legrand; Paulo H Verardi; Leslie A Jones; Tilahun Yilma; Bertram L Jacobs
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

7.  Progressive Vaccinia Acquired through Zoonotic Transmission in a Patient with HIV/AIDS, Colombia.

Authors:  Katherine Laiton-Donato; Paola Ávila-Robayo; Andrés Páez-Martinez; Paula Benjumea-Nieto; José A Usme-Ciro; Nicole Pinzón-Nariño; Ivan Giraldo; Diego Torres-Castellanos; Yoshinori Nakazawa; Nishi Patel; Kimberly Wilkins; Yu Li; Whitni Davidson; Jillybeth Burgado; Panayampalli Subbian Satheshkumar; Ashley Styczynski; Matthew R Mauldin; Martha Gracia-Romero; Brett W Petersen
Journal:  Emerg Infect Dis       Date:  2020-03       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.